Did the FDA miss signals on a troubled heart drug?

By Jeanne Lenzer

It has been a rough eight months for the drug maker Actavis, Inc. and its powerful heart drug, Digitek. Following repeated Food and Drug Adm

Related to this story

FDA's flimsy recall power for food imports puts public at risk, watchdog says

By Aaron Mehta and Ben Wieder

FDA enforcement actions way down

By The Center for Public Integrity

Amid digital records surge, a lack of policing by the FDA

By Emma Schwartz and Fred Schulte

Most drug trial results analyzed by FDA hidden from view

By Naseem Miller

Excerpts from this story referencing "digoxin":

"… headquartered in Little Falls, New Jersey, sold Digitek, a generic form of digoxin, until it was withdrawn on April 25. The drug was distributed by Mylan Pha …"

"… under a “UDL” label. Digitek accounted for roughly one-half of all the digoxin on the market in the United States.Barbara Guthrie of Denver, Colorado, wh …"

"… k are similar to side effects that can occur when using any formulation of digoxin, even under prescribed conditions to treat heart failure and abnormal hear …"

"… “Any medical student can tell you about the narrow margin of safety with digoxin.” As soon as officials knew that some patients could have been given dou …"